BOSTON, Nov. 22, 2016 /PRNewswire/ -- Manna Molecular Science LLC ("MMS") of Boston, announces an exclusive licensing agreement with Temescal Wellness of Maryland ("Temescal") for the sale and wholesale distribution of transdermal patches in Maryland, bringing top pharmaceutical talent and experience to bear on therapeutic cannabis delivery systems.
Maryland is "a cornerstone of the Northeast corridor's cannabis marketplace," said MMS CEO Nial DeMena, adding "Temescal exemplifies the kind of operator with whom we do business," citing their successful medical cannabis licensing campaigns in New Hampshire, Massachusetts and Maryland. DeMena said both organizations are growing in markets across the country with an outsized demand for truly medical cannabis products. MMS transdermal patch production has begun with clients in NH, MA and CA, and uses its proprietary MannaBot One ("MB1") to repeatably and accurately formulate patches. MB1 empowers even smaller-scale operators to grow rapidly without sacrificing quality or consistency, and allows operators to (1) manufacture transdermal patches on-demand, (2) scale the dose up or down, or (3) adjust cannabinoid ratios depending on patient needs, all with a software-enabled, easily-operated desktop unit. MMS does not handle cannabis, but instead provides an installation kit that allows licensed operators to create its expertly designed transdermal patches on site. MMS was founded by a cannabis testing lab operator, an operations expert, and an MIT Ph.D. formulation chemist, and its product development team includes eminent transdermal expert Dr. Ken Miller, and a DMPK expert from Genzyme. MMS continues to attract new talent to its product and sales teams, and is expanding its portfolio with best-in-class infused products, technologies and delivery forms.